Table 1 Main clinical data of the study population.
From: COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City
Parameters | Parameters | ||
|---|---|---|---|
Age (year), median (Q1–Q3) | 73 (60–82) | Co-morbidity, n (%) | |
Gender, n (%) | Absent | 2 (3%) | |
Males | 47 (69%) | 1 | 8 (12%) |
Females | 21 (31%) | 2 | 15 (22%) |
≥3 | 41 (60%) | ||
NA | 2 (3%) | ||
Race, n (%) | Treatment, n (%) | ||
White | 38 (56%) | Anticoagulant | 18 (26%) |
Hispanic | 17 (25%) | Antiviral | 1 (2%) |
Black | 7 (10%) | Immunomodulant | 7 (10%) |
Asian | 2 (3%) | Anticoagulant + antiviral | 6 (9%) |
Other | 4 (6%) | Anticoagulant + immunomodulant | 25 (37%) |
Only supportive | 11 (16%) | ||
Smoke, n (%) | |||
Yes | 3 (4%) | Days intubated, median (Q1–Q3) | 0 (0–5) |
Former | 18 (26%) | ||
No | 35 (52%) | ||
NA | 12 (18%) | ||
Days of disease, median (Q1–Q3) | 11 (8–19) | ||
Fever (°C) | |||
≤37.5 | 17 (25%) | 7.5 (4.825–11.45) | |
37.6–38.5 | 16 (24%) | WBC (109/L), median (Q1–Q3) | |
>38.6 | 28 (41%) | 0.77 (0.5–1) | |
NA | 7 (10%) | ALC (109/L) median (Q1–Q3) | |
PLT (109/L) median (Q1–Q3) | 172 (11.5–237.5) | ||
Cough, n (%) | |||
Yes | 32 (47%) | DD (109/L) median (Q1–Q3) | 2447 (1110.75–6885.3) |
No | 32 (47%) | ||
NA | 4 (6%) | ||
CRP (mg/L) median (Q1–Q3) | 55.2 (24.4–206.2) | ||
Shortness of breath, n (%) | |||
Yes | 54 (80%) | ESR (mm/h) median (Q1–Q3) | 68 (36–104) |
No | 11 (16%) | ||
NA | 3 (4%) | IL-6 (ng/L) median (Q1–Q3) | 122.5 (45–231.5) |
